Fortress Biotech, Inc. 8-K

What Happened

• On March 30, 2026, Fortress Biotech filed an 8-K reporting that its majority-owned subsidiary, Cyprium Therapeutics, closed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million in gross proceeds pursuant to a previously disclosed asset purchase agreement.
• Following the PRV sale, Cyprium redeemed all outstanding shares of its 9.375% Perpetual Preferred Stock under the securities’ terms. Fortress owns 80.4% of Cyprium’s common stock (as-converted) and expects to receive its pro rata share of future dividends from Cyprium.

Key Details

• PRV sale closed: $205.0 million in gross proceeds (March 30, 2026).
• Fortress ownership of Cyprium: 80.4% of outstanding common stock (as-converted).
• Expected cash to Fortress: an aggregate of at least $100.0 million from Cyprium via potential future dividends and intercompany agreements (including intercompany debt, interest and accrued expenses).
• Amounts are subject to change due to Cyprium’s obligation to pay 20% of PRV sale proceeds to an NIH institute, tax liabilities, future board-approved dividends, and other obligations.

Why It Matters

• The transaction generates significant liquidity in a business that often relies on milestone and asset monetizations, and Fortress should receive a large cash inflow through its majority stake and intercompany claims.
• Investors should note the $100M+ expected to flow to Fortress is conditional and may be reduced by the NIH payment, taxes, or other obligations; the filing also contains standard forward-looking statement disclaimers.